329 related articles for article (PubMed ID: 30716315)
1. TAS-203, an oral phosphodiesterase 4 inhibitor, exerts anti-inflammatory activities in a rat airway inflammation model.
Demizu S; Asaka N; Kawahara H; Sasaki E
Eur J Pharmacol; 2019 Apr; 849():22-29. PubMed ID: 30716315
[TBL] [Abstract][Full Text] [Related]
2. Effects of the new benzimidazole derivative TAS-203, an orally active phosphodiesterase 4 inhibitor, on airway inflammation in rats and emetic responses in ferrets.
Asaka N; Kakuo H; Ohmori K; Sasaki E; Togawa M; Yamada S; Oka T; Kiniwa M
Arzneimittelforschung; 2010; 60(9):564-70. PubMed ID: 21117500
[TBL] [Abstract][Full Text] [Related]
3. Current insights on clinical efficacy of roflumilast for treatment of COPD, asthma and ACOS.
Bodkhe S; Nikam M; Sherje AP; Khan T; Suvarna V; Patel K
Int Immunopharmacol; 2020 Nov; 88():106906. PubMed ID: 33182057
[TBL] [Abstract][Full Text] [Related]
4. Effects of ciclamilast, a new PDE 4 PDE4 inhibitor, on airway hyperresponsiveness, PDE4D expression and airway inflammation in a murine model of asthma.
Deng YM; Xie QM; Tang HF; Sun JG; Deng JF; Chen JQ; Yang SY
Eur J Pharmacol; 2006 Oct; 547(1-3):125-35. PubMed ID: 16956605
[TBL] [Abstract][Full Text] [Related]
5. Phloretin attenuates mucus hypersecretion and airway inflammation induced by cigarette smoke.
Wang H; Yang T; Wang T; Hao N; Shen Y; Wu Y; Yuan Z; Chen L; Wen F
Int Immunopharmacol; 2018 Feb; 55():112-119. PubMed ID: 29245072
[TBL] [Abstract][Full Text] [Related]
6. New pharmacotherapy for airway mucus hypersecretion in asthma and COPD: targeting intracellular signaling pathways.
Lai H; Rogers DF
J Aerosol Med Pulm Drug Deliv; 2010 Aug; 23(4):219-31. PubMed ID: 20695774
[TBL] [Abstract][Full Text] [Related]
7. Phosphodiesterase inhibitors in the treatment of inflammatory diseases.
Page CP; Spina D
Handb Exp Pharmacol; 2011; (204):391-414. PubMed ID: 21695650
[TBL] [Abstract][Full Text] [Related]
8. Hesperetin-7,3'-O-dimethylether selectively inhibits phosphodiesterase 4 and effectively suppresses ovalbumin-induced airway hyperresponsiveness with a high therapeutic ratio.
Yang YL; Hsu HT; Wang KH; Han CY; Chen CM; Chen CM; Ko WC
J Biomed Sci; 2011 Nov; 18(1):84. PubMed ID: 22074248
[TBL] [Abstract][Full Text] [Related]
9. [Effect of Yifei Jianpi Recipe on Airway Inflammation and Airway Mucus Hypersecretion of Chronic Obstructive Pulmonary Disease Model Rats].
Wang S; Xiong LL; Ren W; Zhu CD; Li CY; Zhou Q
Zhongguo Zhong Xi Yi Jie He Za Zhi; 2015 Aug; 35(8):993-9. PubMed ID: 26485917
[TBL] [Abstract][Full Text] [Related]
10. Phosphodiesterase 4 inhibition decreases MUC5AC expression induced by epidermal growth factor in human airway epithelial cells.
Mata M; Sarriá B; Buenestado A; Cortijo J; Cerdá M; Morcillo EJ
Thorax; 2005 Feb; 60(2):144-52. PubMed ID: 15681504
[TBL] [Abstract][Full Text] [Related]
11. Pharmacology of a novel, orally active PDE4 inhibitor.
Dastidar SG; Ray A; Shirumalla R; Rajagopal D; Chaudhary S; Nanda K; Sharma P; Seth MK; Balachandran S; Gupta N; Palle V
Pharmacology; 2009; 83(5):275-86. PubMed ID: 19321962
[TBL] [Abstract][Full Text] [Related]
12. Effects of Selective Inhibition of PDE4 by YM976 on Airway Reactivity and Cough in Ovalbumin-Sensitized Guinea Pigs.
Mokrý J; Urbanová A; Medvedová I; Kertys M; Mikolka P; Kosutová P; Mokrá D
Adv Exp Med Biol; 2016; 921():61-70. PubMed ID: 27130219
[TBL] [Abstract][Full Text] [Related]
13. Hesperetin-5,7,3'-O-triacetate suppresses airway hyperresponsiveness in ovalbumin-sensitized and challenged mice without reversing xylazine/ketamine-induced anesthesia in normal mice.
Yang YL; Chen CL; Chen CM; Ko WC
BMC Pharmacol Toxicol; 2017 May; 18(1):39. PubMed ID: 28558784
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of phosphodiesterase activity, airway inflammation and hyperresponsiveness by PDE4 inhibitor and glucocorticoid in a murine model of allergic asthma.
Sun JG; Deng YM; Wu X; Tang HF; Deng JF; Chen JQ; Yang SY; Xie QM
Life Sci; 2006 Oct; 79(22):2077-85. PubMed ID: 16875702
[TBL] [Abstract][Full Text] [Related]
15. An evaluation of roflumilast and PDE4 inhibitors with a focus on the treatment of asthma.
Al-Sajee D; Yin X; Gauvreau GM
Expert Opin Pharmacother; 2019 Apr; 20(5):609-620. PubMed ID: 30722707
[TBL] [Abstract][Full Text] [Related]
16. The preclinical pharmacology of roflumilast--a selective, oral phosphodiesterase 4 inhibitor in development for chronic obstructive pulmonary disease.
Hatzelmann A; Morcillo EJ; Lungarella G; Adnot S; Sanjar S; Beume R; Schudt C; Tenor H
Pulm Pharmacol Ther; 2010 Aug; 23(4):235-56. PubMed ID: 20381629
[TBL] [Abstract][Full Text] [Related]
17. Effects of tadalafil (PDE5 inhibitor) and roflumilast (PDE4 inhibitor) on airway reactivity and markers of inflammation in ovalbumin-induced airway hyperresponsiveness in guinea pigs.
Mokry J; Urbanova A; Medvedova I; Kertys M; Mikolka P; Kosutova P; Mokra D
J Physiol Pharmacol; 2017 Oct; 68(5):721-730. PubMed ID: 29375047
[TBL] [Abstract][Full Text] [Related]
18. [Effect of aminophylline and simvastatin on airway inflammation and mucus hypersecretion in rats with chronic obstructive pulmonary disease].
Wang S; Xiong L; Deng X; Zhou Q; Li C; Ren W; Zhu C
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2016 Jan; 41(1):37-43. PubMed ID: 26819423
[TBL] [Abstract][Full Text] [Related]
19. Phosphodiesterase 4 (PDE4) Inhibitors in the Treatment of COPD: Promising Drug Candidates and Future Directions.
Parikh N; Chakraborti AK
Curr Med Chem; 2016; 23(2):129-41. PubMed ID: 26572614
[TBL] [Abstract][Full Text] [Related]
20. Increased Expression of
Manevski M; Devadoss D; Long C; Singh SP; Nasser MW; Borchert GM; Nair MN; Rahman I; Sopori M; Chand HS
Front Immunol; 2022; 13():803362. PubMed ID: 35774797
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
